Nicolas Ferry

Nicolas Ferry was trained as an M.D., Ph.D. from Paris University. He entered the field of gene therapy during a post-doctoral training at Pasteur Institute in 1989. Nicolas then served as a scientist at the French National Institute for Health Sciences (INSERM) for more than 25 years, including the direction of the UMR INSERM 948 dedicated to biotherapy for acquired and inherited liver diseases from 2009 to 2011. He co-authored more than 120 publications.

Nicolas was appointed as a director for biologics at the French regulatory authority (ANSM) from 2011 to 2016. During that time, he was also member of the Committee for Advanced Therapies (CAT) and of the Scientific Advisory Working Group (SAWP) at EMA.

Nicolas previously served as scientific director for gene and cell therapy at Servier from 2018 to 2020. And as VP and CDO at Coave Therapeutics until 2022. He is now referent for bioproduction and biotherapy at INSERM ITMO Health Technology.

Nicolas is also the founder of NF Consulting, a company dedicated to regulatory consultancy for the development of biologics.